Soquelitinib is under clinical development by Corvus Pharmaceuticals and currently in Phase III for Follicular Lymphoma. According to GlobalData, Phase III drugs for Follicular Lymphoma have a 55% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Soquelitinib’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Soquelitinib overview
Soquelitinib (CPI-818) is under development for the treatment of acute and chronic asthma, systemic sclerosis, cutaneous T-cell lymphoma, follicular lymphoma, T-cell leukemia, angioimmunoblastic T-cell lymphoma, pulmonary fibrosis, psoriasis, renal cell cancer, atopic dermatitis (Inflammatory), unspecified immunological disorders, peripheral T-cell lymphomas, autoimmune lympho-proliferative disease, other auto immune diseases, allergies and solid tumors. It is administered through oral route in the form of capsule. It acts by targeting tyrosine-protein kinase ITK.
It was also under development for the treatment of systemic lupus erythematosus, colon cancer, B cell cancers, acute graft versus host disease in patients receiving bone marrow transplantation, non-small cell lung cancer, renal cell carcinoma (RCC) and melanoma.
Corvus Pharmaceuticals overview
Corvus Pharmaceuticals (Corvus Pharma) is a clinical-stage biopharmaceutical company that primarily focus on the development of indigenous technical knowledge (ITK). The company provides innovative medicines for patients with hard-to-treat cancers and immune diseases. Its products include soquelitinib (CPI-818), ciforadenant (CPI-444), and mupadolimab (CPI-006). Corvus Pharma’s product pipeline also includes adenosine A2B receptor antagonists indigenous technical knowledge inhibitors and myeloid cell suppression. The company operates in the US and the Cayman Islands. Corvus Pharma is headquartered in Burlingame, California, US.
For a complete picture of Soquelitinib’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
